top of page

September 2023

Everads enters license agreement with Kriya Therapeutics for development of ocular gene therapy candidates using Everads' suprachoroidal delivery technology.

For Kriya's press release click here

For Everads' press release click here


January 2023

VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases. 

Delivery of VivaVision's best-in-class molecules via the suprachoroidal space using Everads' technology is expected to lead to novel treatments for retinal diseases.


July 2022

Everads Therapy announced today that Israel’s Innovation Authority (IIA) has awarded a grant to help fund the company’s research and development. Moshe Weinstein, Everads’ CEO, stated that “We are excited to have been awarded this competitive grant, the receipt of which is a validation of the strong business and scientific case for our technology and pipeline. The grant programs of the Israel Innovation Authority are a true catalyst for Israeli companies, and we are honored and humbled to have been chosen.”


August 2020

Global Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targets.

While granting the pharma company exclusivity for specific ocular targets, Everads has retained the right to work on other targets and treatments, both independently and with other partners.

tvst 5_edited.jpg

June 2023

Everads is pleased to announce the publication in Translation Vision Sciences & Technology (TVST), an ARVO journal, of data showing that Everads’ suprachoroidal delivery technology enables safe, rapid and broad delivery throughout the posterior pole in non-human primate models. This work demonstrated that Everads’ technology was able to deliver 150-200 µL of ICG dye to the back of the eye via the suprachoroidal space. The injection was well tolerated in NHP eyes, with rapid distribution into the macular region and throughout the posterior pole. Moshe Weinstein, CEO of Everads, stated that “we are honored to have such a prestigious journal publish this promising data. Demonstrating the efficacy of this technology in non-human primates further confirms the promising results that can be achieved with our technology and we look forward to continuing its development with our collaborators”.


January 2023

We are delighted to attend The Next Generation Ophthalmic Drug Delivery Summit. Join us to discover Everads’ novel delivery technology optimizing the treatment of retinal disease.

צילום מסך 2022-07-08 ב-15.18.28.png

March 2022

Ophthalmology Times: "Suprachoroidal delivery system gets drug to the macula, posterior segment"


July 2020

Everads Therapy featured on European Union's CORDIS website:
The European Union has selected Everads for a publication in the ‘Results in Brief’ section of the European Commission’s CORDIS website.​

go for israel 4_edited_edited_edited_edited.jpg

May 2023

Everads’ invited to present at the 30th GoForIsrael Investment Conference.

Moshe Weinstein, CEO of Everads, presented the company at the GoForIsrael 2023 conference on May 3rd, 2023 in the innovative technologies in biotech session. This conference, in its 30th year, focuses on connecting between leading global investors and Israel’s most innovative technology companies. Organized by Cukierman & Co. and Catalyst Funds, GoforIsrael has been one of the most influential business conferences in Israel for over 25 years.

צילום מסך 2022-11-07 ב-7.06.31.png

September 2022

Everads Therapy Featured at the 3rd Annual Gene Therapy for Ocular Disorders Conference

Everads Therapy announced today that Dr. Yoreh Barak, Director of Vitro-Retina Service at Rambam Medical Center, was invited to present Everads’ suprachoroidal delivery technology at the 3rd Annual Gene Therapy for Ocular Disorders conference held September 13-16th in Boston, Massachusetts. 

Senior Woman

June  2021​

Everads Enters into Collaboration to Evaluate its Suprachoroidal Delivery Technology with a Clinical-Stage Gene Therapy Company

-  Under new collaboration, partner given opt-in right to license specific retinal targets in exchange for pre-agreed license fees, development milestones and royalties

-  Agreement follows a previously-announced option deal with a global pharmaceutical company evaluating Everads' technology

Senior Portrait

March 2020

Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies;

- Agreement Supports Potential of Everads' Novel Technology and Method for Delivery of Posterior Segment Therapeutics to the Suprachoroidal Space.

bottom of page